Literature DB >> 31609155

Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden.

Gary M Oderda1, Anthony J Senagore1, Kellie Morland1, Sheikh Usman Iqbal1, Marla Kugel1, Sizhu Liu1, Ashraf S Habib1.   

Abstract

Opioid-induced respiratory depression (OIRD) and postoperative nausea and vomiting (PONV) are challenging, resource-intensive, and costly opioid-related adverse events (ORAEs). Utilizing the Premier Healthcare Database, we identified patients > 18 years old, who underwent at least one surgical procedure of interest (i.e., cardiothoracic/vascular, general/colorectal, obstetric/gynecologic, orthopedic, or urologic), and received at least one dose of intravenous morphine, hydromorphone, or fentanyl for acute postoperative pain. The incidence of OIRD and PONV using ICD-9 codes, factors influencing these AEs, length of stay (LOS) and related costs were analyzed. Among 592,127 inpatient stays, rates of respiratory depression ranged from 3% (obstetric/gynecologic) to 17% (cardiothoracic/vascular) and nausea/vomiting from 44% (obstetric/gynecologic) to 72% (general/colorectal). Increased odds of OIRD were associated with older age (cardiothoracic/vascular, general/colorectal, obstetric/gynecologic); obesity, respiratory conditions, and sleep apnea (all surgery groups); opioid dose (cardiothoracic/vascular, general/colorectal, orthopedic); and sedative use after day 1. Increased odds of PONV were associated with younger age, female sex, and major disease severity. When respiratory depression or nausea/vomiting was present versus absent, LOS was significantly longer, and hospital costs were higher. In this analysis, OIRD and PONV were more prevalent than previously reported, were associated with identifiable risk factors, and had substantial effects on resource utilization and costs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31609155     DOI: 10.1080/15360288.2019.1668902

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  6 in total

Review 1.  Analgesic Efficacy of Gabapentin and Pregabalin in Patients Undergoing Laparoscopic Bariatric Surgeries: a Systematic Review and Meta-analysis.

Authors:  Ping-Wen Huang; Cheuk-Kwan Sun; Kuo-Chuan Hung; Shao-Chun Wu; Min-Hsien Chiang; Chih-Wei Hsu; Jui-Yi Chen
Journal:  Obes Surg       Date:  2022-05-17       Impact factor: 3.479

Review 2.  Reimagining How We Treat Acute Pain: A Narrative Review.

Authors:  Pablo Castroman; Ovelio Quiroga; Victor Mayoral Rojals; Maria Gómez; Eleni Moka; Joseph Pergolizzi; Giustino Varrassi
Journal:  Cureus       Date:  2022-04-09

Review 3.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

Review 4.  Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update.

Authors:  Erik Stenberg; Luiz Fernando Dos Reis Falcão; Mary O'Kane; Ronald Liem; Dimitri J Pournaras; Paulina Salminen; Richard D Urman; Anupama Wadhwa; Ulf O Gustafsson; Anders Thorell
Journal:  World J Surg       Date:  2022-01-04       Impact factor: 3.352

5.  Developing a risk stratification tool for predicting opioid-related respiratory depression after non-cardiac surgery: a retrospective study.

Authors:  Sounak Roy; Stephen Bruehl; Xiaoke Feng; Matthew S Shotwell; Thomas Van De Ven; Andrew D Shaw; Miklos D Kertai
Journal:  BMJ Open       Date:  2022-09-05       Impact factor: 3.006

6.  Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials.

Authors:  Gregory B Hammer; Ashish K Khanna; Cathy Michalsky; Linda Wase; Mark A Demitrack; Roderick Little; Michael J Fossler; Sabry Ayad
Journal:  Pain Ther       Date:  2021-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.